Tumor-released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape from NK Cell Attack

NK cell-based immunotherapy for malignant diseases

(2013) Min Cheng et al.   Cellular & Molecular Immunology

NK cells in immunotolerant organs

(2013) Haoyu Sun et al.   Cellular & Molecular Immunology

Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis

(2013) P. Guha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity

(2011) Gordana Radosavljevic et al.   CLINICAL & EXPERIMENTAL METASTASIS

A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans

(2011) Shigeru Tsuboi et al.   EMBO JOURNAL

A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice

(2010) N. Demotte et al.   CANCER RESEARCH

LFA-1 and CD2 Synergize for the Erk1/2 Activation in the Natural Killer (NK) Cell Immunological Synapse

(2009) Xiaodong Zheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

(2009) Cameron S. Brandt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tumor-Associated Galectin-3 Modulates the Function of Tumor-Reactive T Cells

(2008) W. Peng et al.   CANCER RESEARCH